2026-10-14T20:21:29Z https://api.figshare.com/v2/oai

oai:figshare.com:article/34050060 2026-10-01T18:00:05Z category_7 category_13 category_19 category_21 category_272 category_64 category_128 category_133 portal_5 item_type_1 month_year_10_2026

<p>Overall survival and response rates of Aza/Ven across treatment lines.</p> Tomoaki Ueda (1780057) Kentaro Fukushima (5227799) Sunggi Chi (25157827) Hiroshi Haeno (206672) Goichi Yoshimoto (25157830) Hironori Arai (10964553) Daisuke Ikeda (425740) Motoshi Ichikawa (25157833) Naoto Takahashi (385073) Naoko Hosono (9512304) Takahiro Yamauchi (534724) Takeshi Kondo (600866) Shigeru Kusumoto (785749) Junya Kuroda (81185) Yosuke Minami (464487) Medicine Genetics Pharmacology Biotechnology Environmental Sciences not elsewhere classified Cancer Hematology Plant Biology mutational patterns classified incomplete hematologic recovery improved overall survival aml ); however acute myeloid leukemia 8 %, 52 cri 33 %). type 1 – type 1 (< type 2 framework type 2 (< div >< p differential response patterns >) groups based treatment ngs data azacitidine plus venetoclax cri following aza among 53 first type 1 1 %, treatment response effective treatment ≥ third world cohort tet2 </ response heterogeneity patients treated nras </ line settings line setting line patients generation sequencing frequently observed cytogenetic analyses complete remission clinical variables clinical determinants 53 genes <p>A. Overall survival (OS) of the entire Aza/Ven cohort (n  =  97). Median OS was 16.0 months (95% CI: 14.2–18.8). B. Complete remission rate (CRR) by line of therapy (Aza/Ven). 1st line (n  =  66): CR/CRi (n  =  35), non-CR (n  =  30), N/A (n  = 1). 2^nd line (n = 24): CR/CRi (n = 12), non-CR (n = 11), N/A (n = 1). 3^rd line and beyond (n = 14): CR/CRi (n = 7), non-CR (n = 7). C. CRR by line of therapy (Chemotherapy). 1^st line (n = 109): CR/CRi (n = 65), non-CR (n = 42), N/A (n = 2). 2^nd line (n = 29): CR/CRi (n = 9), non-CR (n = 18), N/A (n = 2). 3^rd line and beyond (n = 25): CR/CRi (n = 5), non-CR (n = 19), N/A (n = 1). Aza, azacitidine; CR, complete remission; CRi, CR with incomplete hematologic recovery; N/A, not available; Ven, venetoclax.</p> 2026-10-01T18:00:01Z Image Figure 10.1371/journal.pone.0357898.g001 https://figshare.com/articles/figure/_p_Overall_survival_and_response_rates_of_Aza_Ven_across_treatment_lines_p_/34050060 CC BY 4.0